Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Stuns Merck With Demand For Additional Daxas Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE says it wants Merck to carry out an additional clinical trial of Daxas in conjunction with triple therapy for COPD, if the company is to get its drug into the NHS.

You may also be interested in...



European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical Benefit, But Convergence May Come

It is becoming increasingly clear that NICE and IQWiG have very different concerns on the reimbursement front, but it is only a matter of time before IQWiG gets its teeth into cost-benefit analyses

Novartis Finally Wins Arcapta Approval, Having Lost Battle On Desired Dose

Bronchodilator is approved for COPD at a 75 mcg dose, compared to 150 mcg and 300 mcg in Europe. Label nods to quality-of-life data.

Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected

The narrowed indication granted for Forest Laboratories Inc.'s newly approved chronic obstructive pulmonary disease drug Daliresp (roflumilast) means that a quarter of all diagnosed COPD patients, or three million people, will be eligible for treatment, the firm said.

Related Content

Topics

UsernamePublicRestriction

Register

PS072868

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel